Medical Polymers Market Estimated to Experience a Hike in Growth by 2035

Polymers are materials consisting of repetitive units of monomers that are bound together by strong covalent bonds. They are ubiquitous in our daily lives due to their favorable characteristics. Polymers can be divided into various categories, based on their backbone chain, degradation ability, molecular forces, source of origin, structure of monomer chain and morphology. Further, polymers are being employed in the pharmaceutical / medical sector for a myriad of applications, such as pharmaceutical excipients, medical devices (components and coatings), packaging systems for medications, tissue engineering and 3D printing.
The global medical polymers market size is estimated to grow from USD 20.80 billion in 2024 to USD 46 billion by 2035, representing a CAGR of 7.5% during the forecast period till 2035.
It is important to mention that the manufacturing of pharmaceutical / medical polymers needs to be carried out in a controlled environment with strict adherence to regulatory guidelines in order to maintain the product quality and performance. A variety of novel polymers have also been developed that respond to external stimulus (electric or magnetic field, enzymes, pH, temperature and ultrasound waves), thereby modifying the release of the medication from the dosage form are targeting specific areas in the body. In addition, technological advancements in this domain have led to the development of biodegradable polymers; these polymers are resorbed in the body after fulfilling their function.
Driven by the rising demand for novel medical therapeutics and devices, and the ongoing efforts for the development of pharmaceutical polymers / medical polymers having improved biocompatibility and functionality, we believe that the pharmaceutical polymers / medical polymers market is likely to witness a steady growth over the coming years.
Pharmaceutical Polymer / Medical Polymer Manufacturers: Market Landscape
The current market landscape features the presence of close to 150 companies that are engaged in the manufacturing of pharmaceutical polymers / medical polymers. Majority of the companies manufacture amino-based polymers including collagen, gelatin, poly-lysines, polyglutamic acid and poly-sarcosines. It is worth mentioning that around 15% of the players develop more than three compositions of pharmaceutical polymers / medical polymers.
The pharmaceutical polymers / medical polymers market is highly fragmented, featuring the presence of established companies, as well as emerging start-ups. Around 35% of the companies engaged in this domain are headquartered in Asia-Pacific; of these, majority are mid-sized players (53%), followed by small firms (27%).
Presently, around 85 companies engaged in this domain manufacture synthetic polymers; this can be attributed to the several benefits offered by them, including resistance to chemicals, high flexibility, reasonable strength and versatility. Further, majority (75%) of the players manufacture thermoplastic polymers for the pharmaceutical / medical domain.
In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities to enhance their manufacturing capabilities and comply with the evolving industry benchmarks.
In order to determine the relative competitiveness of companies engaged in the manufacturing of pharmaceutical polymers / medical polymers, we focused on several relevant parameters, such as, company strength (considering company's size and overall experience in the industry) and product competitiveness (based on the source of polymer, number of type of polymer, biodegradability of polymer and number of application area (s)).
Within North America, pharmaceutical polymer / medical polymer manufacturers that have received a higher score, as per our proprietary scoring criteria, include (arranged in decreasing order of competitiveness score) JenKem Technology, Kraton, NOF America, Poly-Med, Polyzen and Trinseo. Amongst these players, Jenkem Technology has been assigned higher score as it manufactures multiple compositions of pharmaceutical polymers / medical polymers, including amino-based polymer (poly-lysines), polyester (polycaprolactone, polyglycolide / polyglycolic acid, polylactic acid, poly(lactic-co-glycolic acid) and polyether (polyethylene glycol (PEG)).
It is worth mentioning that the company manufactures high quality activated PEG polymers, PEG co-polymers and monodisperse PEGs, from laboratory to commercial scale, under ISO 9001 and ISO 13485 certified quality management system. Further, Kraton claims to manufacture thermoplastic polymers as well as elastomers; specifically, the styrenic block copolymers manufactured by the firm offer improved processability and flexibility and are environment friendly and recyclable.
In terms of company strength, DuPont, Honeywell, International Flavors and Fragrances (IFF) and Dow, each having an experience more than 120 years, emerged as prominent players in this domain. DuPont, a large company, manufactures pharmaceutical polymers / medical polymers for various applications, including implantable medical devices, transdermal adhesives and wound care dressings; these polymers can be sterilized using different methods, such as e-beam irradiation, ethylene oxide sterilization, gamma radiation and steam sterilization.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/medical-poly

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/